Eleven Biotherapeutics | EBIO


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Amgen 228.90 -2.40 -1.04% -9.18%
Bayer 51.77 -0.35 -0.67% -2.03%
Bristol-Myers Squibb 64.58 -0.16 -0.25% 0.62%
Corcept Therapeutics 17.47 -0.43 -2.40% -37.56%
Eleven Biotherapeutics 0.74 0.03 3.70% -55.62%
Eli Lilly 243.10 -2.30 -0.94% 20.14%
Merck & Co 80.73 -0.56 -0.68% -0.55%
PDL BioPharma 2.47 0 0% -23.05%
Pfizer 54.05 0.48 0.90% 48.16%
Rigel Pharmaceuticals 2.30 0.03 1.32% -38.58%
Roche Holding 361.95 -3.75 -1.03% 14.27%
Intrexon 2.96 -0.04 -1.33% -67.61%
X T L Biopharmaceuticals 2.76 0.01 0.36% -20.92%
Ziopharm Oncology 0.86 -0.04 -3.92% -76.08%

Indexes Price Day Year
NASDAQ 14154 -186.23 -1.30% 4.61%
US2000 2024 -38.75 -1.88% -5.48%

Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company with a protein engineering platform, called AMP-Rx, that the Company apply to the discovery and development of protein therapeutics to treat diseases of the eye. The Companys therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to rationally design and engineer proteins to modulate the effects of cytokines. The Companys advanced product candidate is EBI-005, which it designed, engineered and generated using its AMP-Rx platform and is developing as a topical treatment for dry eye disease and allergic conjunctivitis. The Companys EBI-005 program is based on the role that elevated levels of the inflammatory cytokine interleukin-1, or IL-1, play in the initiation and maintenance of the inflammation and pain associated with dry eye disease and the redness and itching associated with allergic conjunctivitis.